Press Releases

Press Releases

Date	Title	View
August 11, 2022	AN2 Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
June 29, 2022	AN2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole for Treatment-Refractory MAC Lung Disease
May 10, 2022	AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 9, 2022	AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
March 24, 2022	AN2 Therapeutics Announces Pricing of Upsized Initial Public Offering
March 16, 2022	AN2 Therapeutics Appoints Dr. Mel Spigelman, M.D. to its Board of Directors
February 16, 2022	AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria
February 10, 2022	AN2 Therapeutics Reports Phase 1b Data for Oral Epetraborole
January 20, 2022	AN2 Therapeutics Provides Regulatory Update and Plan to Initiate Clinical Development for Epetraborole Targeting NTM Lung Disease
January 7, 2022	AN2 Therapeutics Closed $80 Million Series B Financing to Advance Novel Nontuberculous Mycobacterial Lung Disease Program

Investors